Latest Insider Transactions at Cognition Therapeutics Inc (CGTX)
This section provides a real-time view of insider transactions for Cognition Therapeutics Inc (CGTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of COGNITION THERAPEUTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of COGNITION THERAPEUTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2024
|
Aaron G.L. Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+36.96%
|
-
|
|
Jun 07
2024
|
Leslie W. Kreis Director |
BUY
Grant, award, or other acquisition
|
Indirect |
8,500
+36.96%
|
-
|
|
Jun 07
2024
|
Brett P Monia Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+36.96%
|
-
|
|
Jun 07
2024
|
Ellen B Richstone Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+25.76%
|
-
|
|
Jun 07
2024
|
Jack A. Khattar Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+36.96%
|
-
|
|
Jun 07
2024
|
Peggy Wallace Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+13.94%
|
-
|
|
May 01
2024
|
John Brendan Doyle Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,699
-6.7%
|
$8,699
$1.95 P/Share
|
|
Mar 14
2024
|
Lisa Ricciardi CEO & President |
BUY
Open market or private purchase
|
Direct |
5,700
+1.92%
|
$5,700
$1.75 P/Share
|
|
Feb 15
2024
|
Lisa Ricciardi CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+20.8%
|
-
|
|
Feb 15
2024
|
Anthony Caggiano Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+29.76%
|
-
|
|
Feb 15
2024
|
John Brendan Doyle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+13.35%
|
-
|
|
Feb 03
2024
|
Lisa Ricciardi CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
27,828
-11.67%
|
$55,656
$2.29 P/Share
|
|
Feb 03
2024
|
Anthony Caggiano Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,777
-13.53%
|
$25,554
$2.29 P/Share
|
|
Nov 08
2023
|
Aaron G.L. Fletcher Director |
BUY
Grant, award, or other acquisition
|
Indirect |
500,095
+50.0%
|
$500,095
$1.05 P/Share
|
|
Nov 08
2023
|
Leslie W. Kreis Director |
BUY
Grant, award, or other acquisition
|
Indirect |
500,095
+50.0%
|
$500,095
$1.05 P/Share
|
|
Jun 09
2023
|
Aaron G.L. Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Jun 09
2023
|
Leslie W. Kreis Director |
BUY
Grant, award, or other acquisition
|
Indirect |
6,000
+50.0%
|
-
|
|
Jun 09
2023
|
Jack A. Khattar Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Jun 09
2023
|
Ellen B Richstone Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+27.27%
|
-
|
|
Jun 09
2023
|
Peggy Wallace Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+12.01%
|
-
|
|
Jun 09
2023
|
Brett P Monia Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
May 01
2023
|
John Brendan Doyle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,824
+50.0%
|
-
|
|
Feb 03
2023
|
Lisa Ricciardi CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
213,973
+47.29%
|
-
|
|
Feb 03
2023
|
Anthony Caggiano Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
94,406
+50.0%
|
-
|
|
Nov 29
2022
|
Ellen B Richstone Director |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$20,000
$2.65 P/Share
|
|
Nov 28
2022
|
Leslie W. Kreis Director |
BUY
Open market or private purchase
|
Indirect |
16,064
+0.6%
|
$32,128
$2.65 P/Share
|
|
Nov 28
2022
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
16,064
+0.6%
|
$32,128
$2.65 P/Share
|
|
Nov 16
2022
|
Leslie W. Kreis Director |
BUY
Open market or private purchase
|
Indirect |
71,000
+2.62%
|
$71,000
$1.4 P/Share
|
|
Nov 16
2022
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
71,000
+2.62%
|
$71,000
$1.4 P/Share
|
|
Nov 15
2022
|
Peggy Wallace Director |
BUY
Open market or private purchase
|
Direct |
12,500
+24.77%
|
$12,500
$1.2 P/Share
|
|
Nov 15
2022
|
Lisa Ricciardi CEO & President |
BUY
Open market or private purchase
|
Direct |
12,000
+32.88%
|
$12,000
$1.3 P/Share
|
|
Nov 15
2022
|
Leslie W. Kreis Director |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+36.84%
|
$1,500,000
$1.2 P/Share
|
|
Nov 15
2022
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+36.84%
|
$1,500,000
$1.2 P/Share
|
|
Sep 27
2022
|
Golden Seeds Cognition Therapeutics LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,489,682
-100.0%
|
-
|
|
Sep 27
2022
|
Peggy Wallace Director |
BUY
Other acquisition or disposition
|
Direct |
22,461
+46.87%
|
-
|
|
Oct 13
2021
|
Peggy Wallace Director |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$36,000
$12.0 P/Share
|
|
Oct 13
2021
|
Mark H. Breedlove Director |
SELL
Open market or private sale
|
Indirect |
11
-0.0%
|
$132
$12.0 P/Share
|
|
Oct 13
2021
|
Mark H. Breedlove Director |
BUY
Conversion of derivative security
|
Indirect |
404,451
+28.67%
|
$0
$0.03 P/Share
|
|
Oct 13
2021
|
Ogden Cap Associates, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
74
-0.0%
|
$888
$12.0 P/Share
|
|
Oct 13
2021
|
Ogden Cap Associates, LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
27,471
+1.23%
|
$0
$0.03 P/Share
|
|
Oct 13
2021
|
Ogden Cap Associates, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,182,981
+27.32%
|
-
|
|
Oct 13
2021
|
Golden Seeds Cognition Therapeutics LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,477,449
+29.89%
|
-
|
|
Oct 13
2021
|
Golden Seeds Cognition Therapeutics LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
33
-0.0%
|
$396
$12.0 P/Share
|
|
Oct 13
2021
|
Golden Seeds Cognition Therapeutics LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
12,276
+0.56%
|
$0
$0.03 P/Share
|
|
Oct 13
2021
|
Aaron G.L. Fletcher Director |
BUY
Conversion of derivative security
|
Indirect |
3,689,437
+44.16%
|
-
|
|
Oct 13
2021
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
190,000
+20.92%
|
$2,280,000
$12.0 P/Share
|
|
Oct 13
2021
|
Aaron G.L. Fletcher Director |
SELL
Open market or private sale
|
Indirect |
90
-0.02%
|
$1,080
$12.0 P/Share
|
|
Oct 13
2021
|
Aaron G.L. Fletcher Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
33,495
+8.0%
|
$0
$0.03 P/Share
|
|
Oct 13
2021
|
Bios Memory Spv I, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,265,423
+43.68%
|
-
|
|
Oct 13
2021
|
Bios Memory Spv I, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
190,000
+20.92%
|
$2,280,000
$12.0 P/Share
|